vs

Side-by-side financial comparison of DLH Holdings Corp. (DLHC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $68.9M, roughly 1.0× DLH Holdings Corp.). DLH Holdings Corp. runs the higher net margin — -1.9% vs -49.0%, a 47.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -24.1%). DLH Holdings Corp. produced more free cash flow last quarter ($-4.8M vs $-84.7M).

DLH Holdings Corp. is a U.S.-based provider of technology-enabled healthcare, logistics, engineering, and mission support services primarily serving federal government agencies including the Department of Veterans Affairs, Department of Defense, and Department of Health and Human Services, as well as select state and local government clients across core public service segments.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

DLHC vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.0× larger
VRDN
$70.6M
$68.9M
DLHC
Growing faster (revenue YoY)
VRDN
VRDN
+81982.3% gap
VRDN
81958.1%
-24.1%
DLHC
Higher net margin
DLHC
DLHC
47.1% more per $
DLHC
-1.9%
-49.0%
VRDN
More free cash flow
DLHC
DLHC
$79.9M more FCF
DLHC
$-4.8M
$-84.7M
VRDN

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
DLHC
DLHC
VRDN
VRDN
Revenue
$68.9M
$70.6M
Net Profit
$-1.3M
$-34.6M
Gross Margin
Operating Margin
2.1%
-56.7%
Net Margin
-1.9%
-49.0%
Revenue YoY
-24.1%
81958.1%
Net Profit YoY
-218.7%
54.9%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLHC
DLHC
VRDN
VRDN
Q4 25
$68.9M
Q3 25
$81.2M
$70.6M
Q2 25
$83.3M
Q1 25
$89.2M
Q4 24
$90.8M
Q3 24
$96.4M
Q2 24
$100.7M
Q1 24
$101.0M
Net Profit
DLHC
DLHC
VRDN
VRDN
Q4 25
$-1.3M
Q3 25
$-920.0K
$-34.6M
Q2 25
$289.0K
Q1 25
$878.0K
Q4 24
$1.1M
Q3 24
$2.3M
Q2 24
$1.1M
Q1 24
$1.8M
Operating Margin
DLHC
DLHC
VRDN
VRDN
Q4 25
2.1%
Q3 25
2.8%
-56.7%
Q2 25
4.5%
Q1 25
5.7%
Q4 24
6.2%
Q3 24
6.6%
Q2 24
5.7%
Q1 24
5.9%
Net Margin
DLHC
DLHC
VRDN
VRDN
Q4 25
-1.9%
Q3 25
-1.1%
-49.0%
Q2 25
0.3%
Q1 25
1.0%
Q4 24
1.2%
Q3 24
2.4%
Q2 24
1.1%
Q1 24
1.8%
EPS (diluted)
DLHC
DLHC
VRDN
VRDN
Q4 25
$-0.09
Q3 25
$-0.07
Q2 25
$0.02
Q1 25
$0.06
Q4 24
$0.08
Q3 24
$0.16
Q2 24
$0.08
Q1 24
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLHC
DLHC
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$257.0K
$490.9M
Total DebtLower is stronger
$133.5M
Stockholders' EquityBook value
$112.2M
$503.0M
Total Assets
$283.5M
$577.1M
Debt / EquityLower = less leverage
1.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLHC
DLHC
VRDN
VRDN
Q4 25
$257.0K
Q3 25
$125.0K
$490.9M
Q2 25
$194.0K
Q1 25
$196.0K
Q4 24
$451.0K
Q3 24
$342.0K
Q2 24
$423.0K
Q1 24
$238.0K
Total Debt
DLHC
DLHC
VRDN
VRDN
Q4 25
$133.5M
Q3 25
$128.0M
Q2 25
$138.3M
Q1 25
$147.3M
Q4 24
$162.2M
Q3 24
$149.4M
Q2 24
$160.9M
Q1 24
$164.8M
Stockholders' Equity
DLHC
DLHC
VRDN
VRDN
Q4 25
$112.2M
Q3 25
$113.0M
$503.0M
Q2 25
$113.7M
Q1 25
$112.8M
Q4 24
$111.4M
Q3 24
$110.1M
Q2 24
$108.6M
Q1 24
$106.8M
Total Assets
DLHC
DLHC
VRDN
VRDN
Q4 25
$283.5M
Q3 25
$290.7M
$577.1M
Q2 25
$299.3M
Q1 25
$306.6M
Q4 24
$325.0M
Q3 24
$314.4M
Q2 24
$325.0M
Q1 24
$325.9M
Debt / Equity
DLHC
DLHC
VRDN
VRDN
Q4 25
1.19×
Q3 25
1.13×
Q2 25
1.22×
Q1 25
1.31×
Q4 24
1.46×
Q3 24
1.36×
Q2 24
1.48×
Q1 24
1.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLHC
DLHC
VRDN
VRDN
Operating Cash FlowLast quarter
$-4.8M
$-84.6M
Free Cash FlowOCF − Capex
$-4.8M
$-84.7M
FCF MarginFCF / Revenue
-7.0%
-120.1%
Capex IntensityCapex / Revenue
0.1%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLHC
DLHC
VRDN
VRDN
Q4 25
$-4.8M
Q3 25
$10.7M
$-84.6M
Q2 25
$9.6M
Q1 25
$14.5M
Q4 24
$-11.5M
Q3 24
$12.4M
Q2 24
$4.6M
Q1 24
$5.2M
Free Cash Flow
DLHC
DLHC
VRDN
VRDN
Q4 25
$-4.8M
Q3 25
$10.7M
$-84.7M
Q2 25
$9.4M
Q1 25
$14.0M
Q4 24
$-12.1M
Q3 24
$12.2M
Q2 24
$4.5M
Q1 24
$4.9M
FCF Margin
DLHC
DLHC
VRDN
VRDN
Q4 25
-7.0%
Q3 25
13.1%
-120.1%
Q2 25
11.2%
Q1 25
15.6%
Q4 24
-13.3%
Q3 24
12.7%
Q2 24
4.4%
Q1 24
4.9%
Capex Intensity
DLHC
DLHC
VRDN
VRDN
Q4 25
0.1%
Q3 25
0.0%
0.2%
Q2 25
0.3%
Q1 25
0.6%
Q4 24
0.6%
Q3 24
0.2%
Q2 24
0.2%
Q1 24
0.3%
Cash Conversion
DLHC
DLHC
VRDN
VRDN
Q4 25
Q3 25
Q2 25
33.12×
Q1 25
16.52×
Q4 24
-10.35×
Q3 24
5.42×
Q2 24
4.06×
Q1 24
2.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLHC
DLHC

Sales Channel Directly To Consumer$64.5M94%
Sales Channel Through Intermediary$4.4M6%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons